Preoperative imaging features: Are they useful tools for predicting IDH1 mutation status in gliomas Grades II–IV?

Martin Andres Merenzon1, Jose Ignacio Gómez Escalante2, Diego Prost2, Eduardo Seoane4, Alejandro Mazzon1, Érica Rojas Bilbao2

Departments of 1Neurosurgery, 2Diagnosis, Pathology, 3Neuro-Oncology, Oncology, Instituto de Oncología Ángel H Roffo, 4Department of Neurosurgery, “José María Ramos Mejía” General Hospital, Buenos Aires, Argentina.

E-mail: *Martin Andres Merenzon - martinmeren@gmail.com; Jose Ignacio Gómez Escalante - jgomezescalante@yahoo.com.ar; Diego Prost - dieprost@gmail.com; Eduardo Seoane - edumonedu@yahoo.com; Alejandro Mazzon - alemazzon@yahoo.com.ar; Érica Rojas Bilbao - ericarbilbao_2008@yahoo.com.ar

*Corresponding author: Dr. Martin Andres Merenzon, Department of Neurosurgery, Instituto de Oncología Ángel H Roffo, Buenos Aires, Argentina.

INTRODUCTION

The 2016 and 2021 World Health Organization (WHO) central nervous system (CNS) tumor classification generated a conception shift on how to diagnose and understand gliomas by adding molecular diagnosis, such as isocitrate dehydrogenase (IDH) mutation or 1p19q codeletion...
status, to the classic histologic classification. It is already known that these biomolecular parameters have a reliable prognostic value.\cite{11,22,26} However, an invasive procedure is required to determine them. Finally, these biomarkers are still not widely available in middle- and low-income countries.\cite{12,18}

There is evidence that gliomas have a predilection for the frontal, temporal, and insular lobe.\cite{2,3,7,8,14,16,20,25} In turn, it was also determined that the molecular profiles of gliomas varied from one cerebral lobe to another.\cite{2,3,5,13,19,20,27} However, since the 19th century, the location of tumors was considered following a descriptive criterion of a lobar division of the brain whose limits were arbitrary. Yasargil et al. proposed that the location of neoplastic lesions in the CNS should be understood following a biological cerebral division. In this way, he defined functional compartments by their embryological, metabolic, and cytoarchitectural characteristics, among others.\cite{25,19} Furthermore, several studies have suggested associations between specific contrast enhancement (CE) patterns and IDH mutation status.\cite{1,9,14,23} However, to the best of our knowledge, there are no widely accepted results. The use of neuroimaging features for prediction of the molecular diagnosis of gliomas according to the 2021 WHO classification is still in process of validation.

We hypothesize that imaging characteristics correlate with biological behavior of gliomas which is, in turn, strongly related to their genotype. In this study, we investigate whether there is an association between IDH1 mutation status and several radiological characteristics. The location of the lesions was defined in a novel way according to the division in cerebral functional compartments proposed by Yasargil,\cite{25} an approach seldom used in the previous reports.\cite{10} Our purpose is to better understand gliomas clinical characteristics and to evaluate the usefulness of imaging features in presurgical magnetic resonance imaging (MRI) to predict the R132H mutation in the IDH1 gene in patients with Grades II–IV gliomas.

**MATERIALS AND METHODS**

The study has been approved by both Institutional Research Ethics Committees before experiment was started and has been conducted in accordance with the principles set forth in the Helsinki Declaration of 1975, as revised in 2000.

**Patients’ selection and study design**

An observational, epidemiological, retrospective, and multicenter study was designed.

Patients with a diagnosis of cerebral glioma between January 2014 and December 2021 were identified and analyzed. All the data were obtained from the records of both institutions, which are publicly funded. All patients included were adults, underwent biopsy or tumor resection, and had an MRI (1.5 or 3T) available for review done before their first surgery. Patients’ age was considered at the date of their first surgery. Accessible neuroimaging consisted of at least T2-weighted, FLAIR, T1-weighted, and T1-weighted postcontrast sequences. Patients with ependymomas and choroid plexus tumors were excluded from the study.

The cases diagnosed between 2014 and 2020 according to the 2007 or 2016 WHO classification were reviewed at the Institute of Oncology “Ángel H. Roffo” by a single neuropathologist (JIGE). Molecular testing was done and the diagnosis was reclassified according to the 2021 WHO classification.

**Molecular analysis**

All genetic testing was done at the Department of Diagnosis of the Institute “Roffo.” IDH1 mutation analysis was performed by immunohistochemistry using a monoclonal antibody against IDH1-R132H (H09, Dianova, Hamburg, Germany) in all specimens. Furthermore, by immunohistochemistry, alpha-thalassemia/mental retardation X-linked (ATRX) expression (AX1 clon, Dianova, Hamburg, Germany), p53 staining (D07 clon, Leica, Buffalo Grove, United States of America), and glial fibrillary acidic protein (EP672Y clon, Roche-Ventana, Oro Valley, United States of America) were tested. Finally, CDKN2A homozygous deletion and 1p/19q codeletion analysis were performed by fluorescence in situ hybridization by means of double detection with a specific DNA molecular probe (ZytoLight SPEC CDKN2A/CEN 9 and 1p36/1q25 and 19q13/19q13 dual color probe, Bremerhaven, Germany). The latter was tested in all gliomas except in glioblastomas (GBMs). This decision was based on the diagnostic algorithm proposed by the WHO.\cite{11} If despite histological analysis and biomolecular testing, an uncertain diagnosis was rendered, the tumor was classified as “Diffuse Glioma, not otherwise specified (NOS).”

**Imaging characteristics**

Preoperative contrast-enhanced MRIs were reviewed. Patients’ images were classified as “CE” or “non-CE” according to the T1-weighted postcontrast sequences. “CE” was defined as any contrast-enhancing nonvascular lesion, when compared with the noncontrast T1 images, regardless of its pattern of enhancement or appearance. In addition, tumor borders were categorized as "sharp” or “indistinct.”

Two of the authors evaluated the images independently, and when their decisions were not concordant, they met to discuss and agreed on the final classification.
Topography

Due to the infiltrative nature of gliomas, when there was a single lesion that did not enhance with contrast, the tumor topography was considered where the epicenter of the lesion in the T2-weighted and FLAIR sequences was located. In gliomas that did enhance with gadolinium, their location was considered according to the epicenter of the tumor in the T1-weighted postcontrast sequences. The classification method was the same as explained above for other imaging characteristics.

The tumors' cerebral topography was classified as follows, according to the functional compartments proposed by Yasargil et al.: (A) neocortical telencephalon: comprised by structures with six cortical layers. (a) Frontal lobe: superior, middle, and inferior frontal gyrus; (b) central lobe: precentral, paracentral, and postcentral gyrus; (c) parietal lobe: superior and inferior parietal lobe and precuneus; (d) occipital lobe: cuneus, superior, middle, and inferior occipital gyrus, lingual, and temporop-occipital gyrus (posterior third); (e) temporal lobe: superior, middle, and inferior temporal gyrus and temporop-occipital gyrus (anterior two-thirds). (B) Mesocortical telencephalon (paralimbic system): comprised by structures with 3–5 cortical layers, which include the insular lobe, cingulate gyrus, parahippocampal gyrus, temporal pole, and orbital gyri. (C) Allocortical telencephalon (limbic system): comprised by structures with no definite lamination to two-layered cortex, which include the amygdala, hippocampal and piriform cortex, septal regions, and substantia innominata. (D) Central nuclei: diencephalon, basal ganglia, and brainstem. (E) Ventricles.

If one lesion occupied two or more compartments, approximately equal in volume, without normal brain interposed, the topography was named "combined."

A glioma was classified as "multicentric" if the patient presented two or more lesions in any given compartment with normal brain interposed between them.

An "eloquent area" was defined as a cortical cerebral area whose function cannot be replaced in case of injury (e.g., the primary sensorimotor area, speech centers, or insula).

Finally, the side of the lesion was systemized as "left," "right," or "bilateral."

Statistical analysis

Data were analyzed through a descriptive analysis. The association between imaging features and IDH1 mutation status was tested using the Chi-squared test or Fisher's exact test on occasions when frequencies were <5. In all tests, a two-tailed \( P < 0.05 \) was considered statistically significant.

RESULTS

Of 111 patients initially evaluated, 108 met the inclusion criteria, 55.6% were male, with a mean age of 50.1 years (19–84 years). About 75.9% of the samples were obtained by resection, 24.1% by biopsy. The most frequent diagnosis was GBM IDH1-Wt (58/108 = 53.7%). Only considering gliomas Grades II–III, diffuse astrocytoma, IDH1-Mut/ATRX-Mut (11/108 = 10.2%) was the most frequent. There were 13 cases categorized as diffuse gliomas NOS, all of them Grade II and IDH1-Wt. Five of them were midline gliomas, located in the central nuclei compartment. The other Grade II (\( n = 20 \)) gliomas were IDH1-Mut. Finally, 9/15 (60%) of the Grade III gliomas were IDH1-Mut. The patients’ characteristics and neuroimaging findings are summarized in Table 1.

Addressing the hypothesis of our research, we looked for an association between the molecular profile and imaging characteristics in presurgical MRI. In Table 2, it is observed that gliomas Grades II–III (33 Grade II and 15 Grade III cases, considering the integrated diagnosis) were very heterogeneous without any significant association. On the other hand, GBM presented more homogeneous characteristics, with a preponderance of CE and sharp borders. Of the 55 CE GBM, 25 were ring-enhancing lesions with the central necrosis. Considering all of the gliomas, CE was significantly associated with IDH1-Wt (\( P < 0.00002 \)). In addition, the positive predictive value of CE for IDH1-Wt was of 87.1% (95%CI: 77.1–93.3%). Furthermore, the negative predictive value of non-CE for IDH1-Mut was of 52.6% (95%CI: 37.3–67.5%). We observed that 33.3% (\( n = 5/15 \) cases) of Grade III gliomas and that 5.2% (\( n = 3/58 \)) of GBM did not enhance with gadolinium. There were 5 (15.2%) Grade II gliomas that did enhance with contrast. Three of them were IDH1-Wt and their diagnosis was diffuse glioma NOS.

When analyzing a possible association between genotype and topography, considering Grades II–III gliomas [Table 3], 66.7% (18/27) with IDH1-Mut were located in the neocortex (13 Grade II and five Grade III). In contrast, only 28.6% (6/21) IDH1-Wt (three Grade II and three Grade III cases) were located in that compartment. Moreover, 75% of gliomas Grades II–III localized in the neocortex were IDH1-Mut, but 61.5% (8/13) of the ones localized in the meso/allocortex were IDH1-Mut (six Grade II and two Grade III). These results did not achieve a statistical significance [Table 3].
DISCUSSION

In this investigation, we found that CE is statistically associated with an IDH1-Wt, in low- and high-grade gliomas. Given its positive predictive value of 87.1%, it can be considered a useful characteristic for predicting an IDH1-Wt. On the contrary, according to our results, non-CE is not a good predictor of an IDH1-Mut. This is because the negative predictive value, that is, the probability that the patient has a mutated IDH1 tumor since the MRI does not show CE, was of 52.6%. This is relevant given the general impression of inferring a low-grade glioma from lesions that do not enhance with gadolinium in the MRI. Taking this evidence into account is that this concept should be reviewed and that gliomas that do not enhance with contrast should not be underestimated. In summary, no CE is not a good feature for predicting IDH1-Mut gliomas.

It is already known that the presence of CE in gliomas is an imaging characteristic of aggressive tumors and also that it could be an independent prognostic factor, associated with worse total survival. However, the evidence available at the moment on the capacity of prediction of the IDH mutation status by CE in MRI is contradictory. We found investigations that report that there is no significant association, while others report that it is a good predictor. In a recent meta-analysis, it is asserted that IDH-mutant gliomas showed less CE than IDH-Wt. Our research revealed that CE is more useful for predicting an IDH1-Wt in gliomas Grades II–IV, than for suggesting a mutation in IDH1, in accordance with other reports. We decided to analyze gliomas Grades II–IV altogether, to look for tools that would serve in the presurgical stage, when the patients still do not have a definitive diagnosis that enables to differentiate them into high- or low-grade gliomas. Michiwaki et al.[14] reported that gliomas with ring enhancement can be predicted as GBM IDH-Wt with high sensitivity (0.89) and specificity (0.91), and also that ring-enhanced tumors present an unfavorable course. Certainly, prospective studies with more statistical power are needed to continue studying this topic.

We observed that most of the gliomas (65/108 = 60.2%) have their epicenter in the neocortical telencephalic compartment, keeping this distribution even considering Grades II–III and GBM separately. It is known that gliomas have a predilection

| Table 1: Clinical and neuroimaging characteristics, n=108. |
|-----------------|-----------------|-----------------|-----------------|
| Sex, n (%)      | Male        | 60 (55.6)      |
|                 | Female      | 48 (44.4)      |
| Age, mean (range), years | 50.1 (19-84) |
| Type of surgery, n (%)      | Surgical excision | 82 (75.9) |
|                          | Stereotactic biopsy | 26 (24.1) |
| Brain side, n (%)*          | Right hemisphere | 49 (45.4) |
|                          | Left hemisphere | 50 (46.3) |
|                          | Bilateral    | 9 (8.3)        |
| Topography, n (%)*          | Neocortical telencephalon | 65 (60.2) |
|                          | Frontal lobe | 25 (23.1)      |
|                          | Temporal lobe | 12 (11.1)      |
|                          | Parietal lobe | 13 (12.0)      |
|                          | Central lobe | 9 (8.3)        |
|                          | Occipital lobe | 3 (2.8)       |
|                          | Temporo-occipital | 1 (0.9)    |
|                          | Parietotemporal | 1 (0.9)      |
|                          | Parieto-occipital | 1 (0.9)     |
|                          | Mesocortical telencephalon | 20 (18.5)  |
|                          | Allocortical telencephalon | 6 (5.6)   |
|                          | Central nuclei | 6 (5.6)       |
|                          | Ventricles   | 1 (0.9)        |
|                          | Multicentric | 8 (7.4)        |
|                          | Combined     | 2 (1.8)        |
| Eloquent, n (%)          | Eloquent    | 42 (38.9)      |
|                          | Noneloquent | 66 (61.1)      |
| MRI – borders, n (%)      | Sharp       | 74 (68.5)      |
|                          | Indistinct  | 34 (31.5)      |
| MRI – contrast enhancement, n (%) | No | 38 (35.2) |
|                          | Yes         | 70 (64.8)      |

*Percentages may not add up to 100% due to rounding. MRI: Magnetic resonance imaging

| Table 2: Relationship between the WHO grades, molecular factors, contrast enhancement, and tumor borders. |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Histology and WHO grade | IDH1 status | Contrast enhancement | Tumor borders |                      |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Yes | No | P-value | Sharp | Indistinct |                   |
| Gliomas, Grade II, n=33 | IDH1-Mut | 2 | 17 | 0.35 | 12 | 7 | |
|                 | IDH1-Wt | 3 | 11 | 0.4 | 5 | 9 | |
| Gliomas, Grade III, n=15 | IDH1-Mut | 7 | 1 | 0.1 | 4 | 4 | |
|                 | IDH1-Wt | 3 | 4 | 0.3 | 4 | 3 | |
| Astrocytoma Grade IV, n=2 | IDH1-Mut | - | 2 | - | 2 | - | |
| Glioblastoma, n=58 | IDH1-Wt | 55 | 3 | - | 47 | 11 | |
| All, n=108 | IDH1-Mut | 9 | 20 | 0.00002 | 18 | 11 | |
|                 | IDH1-Wt | 61 | 18 | 56 | 23 | |

IDH: Isocitrate dehydrogenase, Mut: Mutated, WHO: World Health Organization, Wt: Wild type
Table 3: Correlations between the WHO grades, molecular factors, and topography.

| Histology and WHO grade | IDH1 status, n (%) | Topography, n (%)* |
|-------------------------|-------------------|------------------|
|                         | Neocortical telencephalon | Meso-allocortical telencephalon | Others |
| Gliomas Grades II–III, n=48 | IDH1-Mut, 27 (100) | 18 (66.7) | 8 (29.6) | 1 (3.7) |
|                         | IDH1-Wt, 21 (100) | 6 (28.6) | 5 (23.8) | 10 (47.6) |
| Astrocytoma Grade IV, n=2 | IDH1-Mut (100) | 1 (50) | - | 1 (50) |
| Glioblastoma, n=58 | IDH1-Wt, 58 (100) | 40 (69) | 13 (22.4) | 5 (8.6) |

*Percentages may not add up to 100% due to rounding. IDH: Isocitrate dehydrogenase, Mut: Mutated, WHO: World Health Organization, Wt: Wild type

for the frontal, temporal, and insular lobe. Although it may be because these cerebral lobes represent more brain volume than the rest, there are reports that assert that gliomas are located in certain brain regions more frequently than expected even after adjusting this difference to tissue volume. To the best of our knowledge, our research is one of the few epidemiological reports that account for this asymmetry in tumor topography using the biological criteria described previously. Furthermore, Yasargil observed that tumors that arise in a compartment grow within its limits except for very aggressive exceptions. In our work, only 4.6% of the gliomas occupied two or more different compartments, in accordance with the 10% reported.

We highlight an investigation that compares the molecular profile of gliomas located in the temporal lobe neocortex with others located in the meso- and allocortex of the mentioned lobule. There are methodological differences with our study that should be mentioned when comparing results. Li et al. did not include all the functional brain compartments, as in our work, but only the telencephalon; nor was it carried out in South-American patients. Leaving these differences aside, the investigation carried out by Li et al. concludes that gliomas Grades II–IV located in the neocortex have a slightly higher incidence of mutated IDH, than those located in the limbic and paralimbic system.

This finding, without having statistical power, is also observed in our research when we found that IDH1-Mut Grades II–III glial tumors have a higher prevalence in the neocortical compartment than in other compartments and that IDH1-Wt, a lower prevalence. One possible explanation proposes that since the glia of different brain regions expresses different growth factors, and oncogenesis occurs in cells that overexpress a specific growth factor, then tumors would only grow in a particular region. A vision based on biological characteristics for division of the brain may contribute to elucidate in the future the pathophysiology of gliomas.

This study has several limitations. The first is that only the IDH1-R132H mutation was evaluated due to the lack of availability in publicly funded institutions in Argentina of the specific techniques for evaluation of other IDH1 and IDH2 mutations. Fortunately, the R132H mutation in the IDH 1 gene represents 95% of IDH1/2 mutations in GBM and 80% in Grades II–III gliomas, so the error that can induce in our results is small or without clinical consequences. Second, the patient sample was sparse to perform statistical analysis to all the tumoral characteristics examined. Finally, the retrospective nature of the work brings several biases inherent to the design. We believe that continuing the investigation prospectively, increasing the number of patients, and evaluating all mutations in IDH1 and IDH2 could contribute to reducing the above-mentioned limitations.

Despite the potential limitations, we consider that the greatest value of this work is focused on the positive finding of CE as a predictor of IDH1-Wt. Furthermore, we highlight the questioning of the concept of inferring a good prognosis glioma due to the fact that the lesion does not enhance with contrast in the MRI. Therefore, continuing in the future, the investigation of a possible association between gliomas genotype and radiological features would allow us to provide a noninvasive clinical prognosis instrument that could also have an impact on therapeutic strategies.

CONCLUSION

CE was a reliable imaging feature for predicting IDH1-Wt gliomas. On the other hand, non-CE did not allow predicting with certainty the IDH1 status. According to our study, the concept that if a glioma does not enhance with contrast which is of good prognosis should be reviewed. Furthermore, most gliomas were located in the neocortical telencephalon. In addition, with the exception of very aggressive tumors, gliomas grew within the limits of a single brain compartment.

Acknowledgments

We thank Antonio Colobraro, M.D. for collaboration on histologic diagnosis, María Florencia Soto for providing language help and Jimena Vicens, M.D. for her contribution to the statistical analysis.

Declaration of patient consent

Patients’ consent not required as patients’ identities were not disclosed or compromised.
Financial support and sponsorship

This work was supported by the National Cancer Institute, Ministry of Health, Argentina [grant numbers 14/2018] and the Florencio Fiorini Foundation [grant 2020], Buenos Aires, Argentina and publication of this article was made possible by the James I. and Carolyn R. Ausman Educational Foundation.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Castet F, Alanya E, Vidal N, Izquierdo C, Mesia C, Ducray F, et al. Contrast-enhancement in supratentorial low-grade gliomas: A classic prognostic factor in the molecular age. J Neurooncol 2019;143:515-23.
2. Darlix A, Deverdun J, Menjot de Champfleur N, Castan F, Zouaoui S, Rigau V, et al. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. J Neurooncol 2017;133:37-45.
3. Darlix A, Gozé C, Rigau V, Bauchet L, Taillandier L, Duffau H. The etiopathogenesis of diffuse low-grade gliomas. Crit Rev Oncol Hematol 2017;109:51-62.
4. Duffau H, Capelle L. Preferential brain locations of low-grade gliomas. Cancer 2004;100:2622-6.
5. Gozé C, Mansour L, Rigau V, Duffau H. Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas. J Neurosurg 2013;118:866-72.
6. Hammad MA, Sawaya R, Shi W, Thall PF, Leids NE. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 1996;27:65-73.
7. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001;95:190-8.
8. Larjavaara S, Mäntylä R, Salminen T, Haapasalo H, Raitanen J, Jääskeläinen J, et al. Incidence of gliomas by anatomic location. Neuro Oncol 2007;9:319-25.
9. Lasocki A, Tsui A, Gaillard F, Tacey M, Drummond K, Stuckey S. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. J Clin Neurosci 2017;39:170-5.
10. Li H, Ren X, Zhang J, Lin S. Mediobasal and lateral temporal gliomas exhibit different growth patterns, surgical outcomes and prognoses. Clin Neurosurg 2015;133:90-5.
11. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol 2021;23:1231-51.
12. Merenzon MA, Escalante JI, Prost D, Seoane E, Mazzon A, Bilbao ER. Algorithm for the integrated diagnosis of gliomas 2021. Our experience. Medicina (B Aires) 2022;82:370-5.
13. Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, et al. Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 2010;120:719-29.
14. Michiwaki Y, Hata N, Mizoguchi M, Hiwatachi A, Kuga D, Hatae R, et al. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification. Clin Neurol Neurosurg 2019;187:105556.
15. Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res 2013;19:764-72.
16. Ostrom QT, Gittleman H, Trott G, Boscia A, Kruckcho C, Barnholtz-Sloan JS. Cbtrus statistical report: Primary brain and other central nervous system tumors diagnosed in the united states in 2013-2017. Neuro Oncol 2020;22:iw1-96.
17. Pierallini A, Bonamini M, Bozzao A, Pantano P, Stefano DD, Ferone E, et al. Supratentorial diffuse astrocytic tumours: Proposal of an MRI classification. Eur Radiol 1997;7:395-9.
18. Prost DM, Merenzon MA, Gómez-Escalante JI, Primavera A, Benítez MV, Gil AS, et al. Effects of time to chemoradiation on high-grade gliomas from the Buenos Aires Metropolitan Area. PLoS One 2021;16:e0249486.
19. Ren X, Cui X, Lin S, Wang J, Jiang Z, Sui D, et al. Co-deletion of chromosome 1p/19q and IDH1/2 mutation in glioma subsets of brain tumors in Chinese patients. PLoS One 2012;7:e32764.
20. Sonoda Y, Shibahara I, Kawaguchi T, Saito R, Kanamori M, Watanabe M, et al. Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol 2015;32:99-104.
21. Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: A systemic review and meta-analysis. Eur Radiol 2019;29:745-58.
22. The Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015;372:2481-98.
23. Yamauchi I, Ohno M, Matsushita Y, Takahashi M, Miyakita Y, Kitagawa Y, et al. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas. Brain Tumor Pathol 2018;35:148-58.
24. Yaşargil MG, von Ammon K, Cavazos E, Doczi T, Reeves JD, Roth P. Tumours of the limbic and paralimbic systems. Acta Neurochir (Wien) 1992;118:40-52.
25. Yaşargil MG. Microneurosurgery of CNS Tumor. Vol. 4. Stuttgart, New York: New York: Georg Thieme Verlag, Thieme Medical Publishers; 1994.
26. Zaninovich RS, Jalon PG, Golan JN. Gliomas: Aspectos biológicos, clínicos y terapéuticos [Gliomas: Biologic, clinical and therapeutic features]. Buenos Aires 2017:1-17-45.
27. Zlatescu MC, Tehrani-Yazdi A, Sasaki H, Megyesi JF, Betensky RA, Louis DN, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001;61:6713-5.

How to cite this article: Merenzon MA, Gómez-Escalante JI, Prost D, Seoane E, Mazzon A, Bilbao ER. Preoperative imaging features: Are they useful tools for predicting IDH1 mutation status in gliomas Grades II–IV? Surg Neurol Int 2022;13:332.